MONTREAL, April 16 /PRNewswire/ -- Osprey Pharmaceuticals Limited, a privately held biotechnology company focused on treating chronic diseases through a family of first-in-class therapeutic proteins, announced today that it has been granted three patents by the U.S. Patent Office. The patents protect the use of conjugated chemokines to selectively and systematically eliminate overactive leukocytes implicated in most chronic diseases, the core technology behind Osprey's Leukocyte Population Modulator (LPM) platform.
